Molecular modelling of human aldehyde oxidase and identification of the key interactions in the enzyme-substrate complex

Daru

Volumn 13, Issue 3, 2005, Pages 82-93

  Dastmalchi, Siavoush ^a   Hamzeh Mivehrod, Maryam ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

3D QSAR; Aldehyde oxidase; Genetic algorithm; Molecular modeling

Indexed keywords

ALDEHYDE OXIDASE; QUINAZOLINE DERIVATIVE; XANTHINE DEHYDROGENASE;

AMINO ACID SEQUENCE; ANALYTIC METHOD; ARTICLE; CHEMICAL INTERACTION; CORRELATION COEFFICIENT; CRYSTAL STRUCTURE; DNA TEMPLATE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME SUBSTRATE; ENZYME SUBSTRATE COMPLEX; EVALUATION; GOLD STANDARD; MOLECULAR DYNAMICS; MOLECULAR MODEL; OXIDATION; PROTEIN FOLDING; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; THREE DIMENSIONAL IMAGING;

EID: 31644441318     PISSN: 15608115     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Williams DA. Drug metabolism. In: Williams DA, Lemke TL, editors. Foye's principles of medicinal chemistry. 5 ed. Philadelphia: Lippincott Williams and Wilkins; 2002. p 199-200.
2. Terao M, Kurosaki M, Demontis S, Zanotta S, Garattini E. Isolation and characterization of the human aldehyde oxidase gene: conservation of intron/exon boundaries with the xanthine oxidoreductase gene indicates a common origin. Biochem J 1998; 332: 383-93.
3. Hall WW, Krenitsky, T.A. Aldehyde oxidase from rabbit liver: Specificity toward purines and their analogs. Arch Biochem Biophys 1986; 251: 36-46.
4. Krenitsky TA, Neil SM, Elion GB, Hitchings GH. A comparison of the specificities of xanthine oxidase and aldehyde oxidase. Arch Biochem Biophys 1972; 150: 585-99.
5. Ghafourian T, Rashidi MR. Quantitative study of the structural requirments of phtalazine/quinazoline derivatives for interaction with human liver aldehyde oxidase. Chem Pharm Bull 2001; 49: 1066-71.
6. Beedham C. Molybdenum hydroxylases: Biological distribution and substrate-inhibitor specifity. In: Ellis GP, West GB, editors. Prog Med Chem. Volume 24. Amsterdam: Elseveir; 1987. p 85-127.
7. Beedham C, Critchley DJP, Rance DJ. Substrate specifity of human aldehyde oxidase towards substituted quinazolines and phthalazines: A comparison with hepatic enzyme from guinea pig, rabbit and baboon. Arch Biochem Biophys 1995; 319: 481-90.
8. Kitamura S, Nakatani K, Ohashi K, Sugihara K, Hosokawa R, Akagawa Y, Ohta S. Extremely high Drug-Reductase activity based on Aldehyde oxidase in monkey liver. Biol Pharm Bull 2001; 24: 856-59.
9. Hille R. Molybdenum and tungsten in biology. Trends Biochem Sci 2002; 27: 360-67.
10. Ambroziak W, Izaguirre, G., Pietruszko, R. Metabolism of retinaldehyde and other aldehydes in soluble extracts of human. J Biol Chem 1999; 274: 33366-73.
11. Clarke SE, Harrell, A.W., Chenery, R.J. Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab Dispos 1995; 23: 251-54.
12. Jordan CG, Rashidi MR, Laljee H, Clarke SE, Brown JE, Beedham C. Aldehyde oxidase-catalysed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J Pharm Pharmacol 1999; 51: 411-18.
13. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194-210.
14. Al-salmy HS. Inter-strain variability in aldehyde oxidase activity in the mouse. Comparative biochemistry and Physiology Part C: Toxicology and Pharmacology 2002; 132: 341-47.
15. Moriwaki Y, Yamamoto T, Yamakita J, Takahashi S, Tsutsumi Z, Higashino K. Zonal distribution of allopurinol-oxidizing enzymes in rat liver. Adv Exp Med Biol 1998; 431: 47-50.
16. Cates LA, Jones GSJ, Good DJ, Tsai HY, Li VS, Caron N, Tu SC, Kimball AP. Cyclophosphamide potentiation and aldehyde oxidase inhibition by phosphorylated aldehydes and acetals. J Med Chem 1980; 23: 300-04.
17. Renwick AB, Ball SE, Tredger JM, Price RJ, Walters DG, Kao J, Scatina JA, Lake BG. Inhibition of zaleplon metabolism by cimetidine in the human liver: in vitro studies with subcellular fractions and precision-cut liver. Xenobiotica 2002; 32: 849-62.
18. Acheampong AA, Chein DS, Lam S, Vekich S, Breau A, Usansky J, Harcourt D, Munk SA, Nguyen H, Garst M, Tang-Liu D. Characterization of brimonidine metabolism with rat, rabbit, dog, monkey and human liver fractions and rabbit aldehyde oxidase. Xenobiotica 1996; 26: 1035-55.
19. Roy SK, Korzekwa KR, Gonzalez FJ, Moschel RC, Dolan ME. Human liver oxidative metabolism of O6-benzylguanine. Biochem Pharmacol 1995; 50: 1385-89.
20. Roy SK, Gupta E, Dolan ME. Pharmacokinetics of O6-benzylguanine in rats and its metabolism by rat liver microsomes. Drug Metab Dispos 1995; 23: 1394-99.
21. Yoshihara S, Ohta S. Involvement of hepatic aldehyde oxidase in conversion of 1-methyl-4-phenyl-2,3-dihydropyridinium (MPTP+) to 1-methyl-4-phenyl-5,6-dihydro-2-pyridone. Arch Biochem Biophys 1998; 360: 93-98.
22. Guo X, Lerner-Tung M, Chen HX, Chang CN, Zhu JL, Chang CP, Pizzorno G, Lin TS, Cheng YC. 5-Fluoro-2-pyrimidinone, a liver aldehyde oxidase-activated prodrug of 5-fluorouracil. Biochem Pharmacol 1995; 49: 1111-16.
23. Harrell AW, Wheeler SM, East P, Clarke SE, Chenery RJ. Use of rat and human in vitro systems to assess the effectiveness and enzymology of deoxyguanine analogs as prodrugs of an antiviral agent. Drug Metab Dispos 1994; 22: 189-93.
24. Berkman CE, Park SB, Wrighton SA, Cashman JR. In vitro-in vivo correlations of human (S)-nicotine metabolism. Biochem Pharmacol 1995; 50: 565-70.
25. Cashman JR, Park SB, Yang ZC, Wrighton SA, 3rd. Jp, Benowitz NL. Metabolism of nicotine by human liver microsomes: stereoselective formation of trans-nicotine N′-oxide. Chem Res Toxicol 1992; 5: 639-46.
26. Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Psychopharmacol 2003; 23: 229-32.
27. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother 2002; 36: 839-51.
28. Obach RS. Potent inhibition of human liver aldehyde oxidase by raloxifene. Drug Metab Dispos 2004; 32: 89-97.
29. Robertson IG, Gamage RS. Methadone: a potent inhibitor of rat liver aldehyde oxidase. Biochem Pharmacol 1994; 47: 584-87.
30. Robertson IG, Bland TG. Inhibition by SKF-525A of the aldehyde oxidase-mediated metabolism of the experimental antitumor agent acridine carboxamide. Biochem Pharmacol 1993; 45: 2159-62.
31. Johnson C, Stubley-Beedham C, Stell JG. Hydralazine: a potent inhibitor of aldehyde oxidase activity in vitro and in vivo. Biochem Pharmacol 1985; 34: 4251-56.
32. S.M. V, Dachtler SL. Effects of sex hormones on hepatic aldehyde oxidase activity C57BL/6J mice. Horm Res 1981; 14: 250-59.
33. Donelli MG, Bartosek I, A. G, Martini A, Colombo T, Pacciarini MA, Modica R. Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect. Cancer Treat Res 1976; 60: 395-401.
34. Zollner H. Handbook of enzyme inhibitors. Weinheim; 1999. 100-01 p.
35. Berman HM, Westbrook J, Feng Z, Gililand G, Bahat TN, Weissig H, Shindyalov PE. The protein data bank. Nucleic Acids Res 2000; 28: 235-42.
36. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic Local Alignment Search Tool. J Mol Biol 1990; 215: 403-10.
37. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22: 4673-80.
38. Enroth C, Eger BT, Okamoto K, Nishino T, Pai EF. Crystal structures of bovine milk xanthine dehydrogenase and xanthine oxidase: Structure-based mechanism of conversion. Biochemistry 2000; 97: 10723-28.
39. Jones DT, Miller RT, Thornton JM. Successful protein fold recognition by optimal sequence threading validated by rigorous blind testing. Proteins: Struct, Funct, Genet 1995; 23: 387-97.
40. Guex N, Peitsch MC. SWISS-MODEL and the Swiss pdb viewer: An environment for comparative protein modelling. Electrophoresis 1997; 18: 2714-23.
41. Berendsen HJC, Van der Spoel D, Van Drunen R. GROMACS: A message-passing parallel molecular dynamics implementation. Comput Phys Commun 1995; 91: 43-56.
42. Lindahl E, Hess B, Van der Spoel D. GROMACS 3.0: A package for molecular simulation and trajectory analysis. J Mol Mod 2001; 7: 306-17.
43. Van Aalten DMF, Bywater R, Findlay JBC, Hendlich M, Hooft RWW, Vriend G. PRODRG, a program for generating molecular toplogies and unique molecular descriptors from coordinates of small molecules. J Comput Aided Mol Des 1996; 10: 255-62.
44. Laskowski RA, MacArthur MW, Moss DS, hornton JM. Procheck: A program to check the stereochemical quality of protein structures. J Appl Crystallogr 1993; 26: 283-91.
45. Morris AL, MacArthur MW, Hutchinson EG, Thornton JM. Stereochemical quality of protein structure coordinates. Proteins: Struct, Funct, Genet 1992; 12: 345-64.
46. Bowie JU, Luthy R, Eisenberg D. A method to identify protein sequences that fold into a known three-dimensional structure. Science 1991; 253: 164-70.
47. Luthy R, Bowie JU, Eisenberg D. Assessment of protein models with three-dimensional profiles. Nature 1992; 356: 83-85.
48. Gregoret LM, Cohen FE. A novel method for the rapid evaluation of packing in protein structures. J Mol Biol 1990; 211: 959-74.
49. Allinger NL. Conformational analysis 130. MM2. A hydrocarbon force field utilizing v1 and v2 torsional terms. J Am Chem Soc 1977; 99: 8127-34.
50. Dewar MJS, Thiel W. Grond states of molecules.39.MNDO results for molecules containing hydrogen, carbon, nitrogen and oxygen. J Am Chem Soc 1977; 99: 4907-17.
51. Jones G, Willett P, Glen RC. Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. J Mol Biol 1995; 245: 43-53.
52. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 1998; 19: 1639-62.
53. Doweyko AM. The hypothetical active site lattice. An approach to modelling active sites from data on inhibitor molecules. J Med Chem 1988; 31: 1396-406.
54. Doweyko AM, Mattes WB. An application of 3D-QSAR to the analysis of the sequence specifity of DNA alkylation by uracil mustard. Biochemistry 1992; 31: 9388-92.
55. Doweyko AM. Three-Dimensional pharmacophores from binding data. J Med Chem 1994; 37: 1769-78.
56. Ferguson DM. Parametrization and evaluation of a flexible water model. J Comput Chem 1995; 16: 501-11.
57. Kabsch W, Sander C. Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 1983; 22: 2577-637.
58. Morris GM, Olson, A.J., Goodsell, D.S. Protein-Ligand docking. In: Clark DE, editor. Evolutionary algorithms in molecular design. Volume 8, Methods and principles in medicinal chemistry. Weinheim: WILLEY-VCH; 2000. p 32-39.
59. Abagyan RA, Totrov MM. Contact area difference (CAD): a robust measure to evaluate accuracy of protein models. J Mol Biol 1997; 268: 678-85.